Halozyme Therapeutics (Halozyme Therapeutics) Price-to-Owner-Earnings : 14.13 (As of Apr. 26, 2024)

Halozyme Therapeutics Price-to-Owner-Earnings Chart

Halozyme Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Price-to-Owner-Earnings		Get a 7-Day Free Trial					-	290.54	14.24	39.08	13.56

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															39.08	22.27	18.32	14.97	13.56

Competitive Comparison of Halozyme Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Halozyme Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Price-to-Owner-Earnings falls into.

Halozyme Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Halozyme Therapeutics's Price-to-Owner-Earnings for today is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics  (NAS:HALO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Halozyme Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description